Alpha 2.0
Login Register
» Articles » PMID: 25199774

Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients Without Clinically Relevant Hepatotoxicity

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 2014 Sep 10
PMID 25199774
Citations 43
Authors
Dong Sik Jung
Frank P Tverdek
Dimitrios P Kontoyiannis
Affiliations
Soon will be listed here.
Abstract

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.

Citing Articles

Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.

Liu A, Xiong L, Wang L, Zhuang H, Gan X, Zou M BMC Infect Dis. 2024; 24(1):581.

PMID: 38867163 PMC: 11170913. DOI: 10.1186/s12879-024-09477-9.

Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Model of () Infection.

Fernandez O, Rosales-Chilama M, Quintero N, Travi B, Wetzel D, Gomez M Antimicrob Agents Chemother. 2021; 66(1):e0142521.

PMID: 34694879 PMC: 8765415. DOI: 10.1128/AAC.01425-21.

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Dadwal S, Hohl T, Fisher C, Boeckh M, Papanicolaou G, Carpenter P Transplant Cell Ther. 2021; 27(3):201-211.

PMID: 33781516 PMC: 9088165. DOI: 10.1016/j.jtct.2020.10.003.

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare.

Hens B, Augustijns P, Lennernas H, McAllister M, Abrahamsson B Front Med (Lausanne). 2021; 8:480706.

PMID: 33748152 PMC: 7973356. DOI: 10.3389/fmed.2021.480706.

Gynecomastia and hypertension in a patient treated with posaconazole.

Thompson 3rd G, Surampudi P, Odermatt A Clin Case Rep. 2020; 8(12):3158-3161.

PMID: 33363898 PMC: 7752548. DOI: 10.1002/ccr3.3376.

References
1.
Dolton M, Ray J, Chen S, Ng K, Pont L, McLachlan A . Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012; 56(11):5503-10. PMC: 3486529. DOI: 10.1128/AAC.00802-12. View
2.
Kraft W, Chang P, van Iersel M, Waskin H, Krishna G, Kersemaekers W . Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014; 58(7):4020-5. PMC: 4068532. DOI: 10.1128/AAC.02448-13. View
3.
Krishna G, Ma L, Martinho M, Preston R, OMara E . A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012; 67(11):2725-30. PMC: 3468079. DOI: 10.1093/jac/dks268. View
4.
Krishna G, Ma L, Martinho M, OMara E . Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012; 56(8):4196-201. PMC: 3421591. DOI: 10.1128/AAC.00222-12. View
5.
Walsh T, Raad I, Patterson T, Chandrasekar P, Donowitz G, Graybill R . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2006; 44(1):2-12. DOI: 10.1086/508774. View